IN2014MN00988A - - Google Patents
Info
- Publication number
- IN2014MN00988A IN2014MN00988A IN988MUN2014A IN2014MN00988A IN 2014MN00988 A IN2014MN00988 A IN 2014MN00988A IN 988MUN2014 A IN988MUN2014 A IN 988MUN2014A IN 2014MN00988 A IN2014MN00988 A IN 2014MN00988A
- Authority
- IN
- India
- Prior art keywords
- compounds
- formula
- cancer
- diseases
- processes
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161552880P | 2011-10-28 | 2011-10-28 | |
| GBGB1118652.5A GB201118652D0 (en) | 2011-10-28 | 2011-10-28 | New compounds |
| PCT/GB2012/052666 WO2013061074A1 (en) | 2011-10-28 | 2012-10-26 | Quinolines as fgfr kinase modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN00988A true IN2014MN00988A (hr) | 2015-04-24 |
Family
ID=45373580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN988MUN2014 IN2014MN00988A (hr) | 2011-10-28 | 2012-10-26 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US9439896B2 (hr) |
| EP (1) | EP2776397B1 (hr) |
| JP (1) | JP6067725B2 (hr) |
| KR (1) | KR102072869B1 (hr) |
| CN (1) | CN104011025B (hr) |
| AU (1) | AU2012328164B2 (hr) |
| BR (1) | BR112014010177B1 (hr) |
| CA (1) | CA2853366C (hr) |
| DK (1) | DK2776397T3 (hr) |
| ES (1) | ES2661003T3 (hr) |
| GB (1) | GB201118652D0 (hr) |
| HU (1) | HUE037458T2 (hr) |
| IN (1) | IN2014MN00988A (hr) |
| MX (1) | MX353806B (hr) |
| RU (1) | RU2625303C2 (hr) |
| WO (1) | WO2013061074A1 (hr) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| GB201020179D0 (en) | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
| GB201118652D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118654D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118675D0 (en) | 2011-10-28 | 2011-12-14 | Astex Therapeutics Ltd | New compounds |
| GB201209609D0 (en) * | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| MY189505A (en) | 2012-10-16 | 2022-02-16 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of roryt |
| ES2619610T3 (es) | 2012-10-16 | 2017-06-26 | Janssen Pharmaceutica Nv | Moduladores de ROR-gamma-t de quinolinilo enlazado con heteroarilo |
| KR20150070350A (ko) | 2012-10-16 | 2015-06-24 | 얀센 파마슈티카 엔.브이. | Ror-감마-t의 페닐 결합 퀴놀리닐 조절제 |
| AR094812A1 (es) | 2013-02-20 | 2015-08-26 | Eisai R&D Man Co Ltd | Derivado de piridina monocíclico como inhibidor del fgfr |
| GB201307577D0 (en) | 2013-04-26 | 2013-06-12 | Astex Therapeutics Ltd | New compounds |
| US9346782B2 (en) * | 2013-10-15 | 2016-05-24 | Janssen Pharmaceutica Nv | Alkyl linked quinolinyl modulators of RORγt |
| EP3560920A1 (en) * | 2013-10-15 | 2019-10-30 | Janssen Pharmaceutica NV | Secondary alcohol quinolinyl modulators of ror gamma t |
| US9221804B2 (en) | 2013-10-15 | 2015-12-29 | Janssen Pharmaceutica Nv | Secondary alcohol quinolinyl modulators of RORγt |
| US9328095B2 (en) | 2013-10-15 | 2016-05-03 | Janssen Pharmaceutica Nv | Heteroaryl linked quinolinyl modulators of RORgammat |
| US10555941B2 (en) | 2013-10-15 | 2020-02-11 | Janssen Pharmaceutica Nv | Alkyl linked quinolinyl modulators of RORγt |
| US9284308B2 (en) | 2013-10-15 | 2016-03-15 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of RORγt |
| CA2927182A1 (en) * | 2013-10-15 | 2015-04-23 | Janssen Pharmaceutica Nv | Quinolinyl modulators of ror.gamma.t |
| US9403816B2 (en) | 2013-10-15 | 2016-08-02 | Janssen Pharmaceutica Nv | Phenyl linked quinolinyl modulators of RORγt |
| CN106456648B (zh) | 2014-03-26 | 2021-11-02 | 阿斯特克斯治疗有限公司 | Fgfr抑制剂和igf1r抑制剂的组合 |
| JO3512B1 (ar) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز |
| EP3848034A1 (en) | 2014-03-26 | 2021-07-14 | Astex Therapeutics Limited | Cmet-inhibitors for use in delaying the emergence in resistance to fgfr inhibitors |
| CA2956270C (en) | 2014-08-18 | 2022-08-09 | Eisai R&D Management Co., Ltd. | Salt of monocyclic pyridine derivative and crystal thereof |
| JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| WO2017050864A1 (en) | 2015-09-23 | 2017-03-30 | Janssen Pharmaceutica Nv | New compounds |
| ES2904513T3 (es) * | 2015-09-23 | 2022-04-05 | Janssen Pharmaceutica Nv | 1,4-Benzodiazepinas biheteroarilo sustituidas y usos de las mismas para el tratamiento del cáncer |
| CN108264510A (zh) * | 2017-01-02 | 2018-07-10 | 上海喆邺生物科技有限公司 | 一种选择性抑制激酶化合物及其用途 |
| AU2019241625A1 (en) | 2018-03-28 | 2020-09-03 | Eisai R&D Management Co., Ltd. | Therapeutic agent for hepatocellular carcinoma |
| CN113087696A (zh) * | 2019-12-23 | 2021-07-09 | 江苏开元药业有限公司 | 喹啉类化合物及其应用 |
| CN114945367A (zh) * | 2020-01-17 | 2022-08-26 | 贝达医药公司 | 作为fgfr激酶抑制剂的哒嗪和1,2,4-三嗪衍生物 |
Family Cites Families (118)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2940972A (en) | 1957-06-27 | 1960-06-14 | Thomae Gmbh Dr K | Tri-and tetra-substituted pteridine derivatives |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| GB9125001D0 (en) | 1991-11-25 | 1992-01-22 | Ici Plc | Heterocyclic compounds |
| AU6909194A (en) | 1993-05-14 | 1994-12-12 | Board Of Regents, The University Of Texas System | Preparation of n-cyanodithioimino-carbonates and 3-mercapto-5-amino-1h-1,2,4-triazole |
| US5700823A (en) | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
| US6331555B1 (en) | 1995-06-01 | 2001-12-18 | University Of California | Treatment of platelet derived growth factor related disorders such as cancers |
| WO1998004689A1 (en) | 1995-07-31 | 1998-02-05 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
| US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
| TW472045B (en) | 1996-09-25 | 2002-01-11 | Astra Ab | Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation |
| SI0991628T1 (en) | 1997-05-28 | 2005-06-30 | Aventis Pharmaceuticals Inc | QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR P56lck TYROSINE KINASES |
| UA71555C2 (en) | 1997-10-06 | 2004-12-15 | Zentaris Gmbh | Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives |
| JP2002534512A (ja) | 1999-01-15 | 2002-10-15 | ノボ ノルディスク アクティーゼルスカブ | 非ペプチドｇｌｐ−１アゴニスト |
| WO2001019825A1 (en) | 1999-09-15 | 2001-03-22 | Warner-Lambert Company | Pteridinones as kinase inhibitors |
| DE10013318A1 (de) | 2000-03-17 | 2001-09-20 | Merck Patent Gmbh | Formulierung enthaltend Chinoxalinderivate |
| WO2002076985A1 (en) | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
| US7569592B2 (en) | 2001-12-18 | 2009-08-04 | Merck & Co., Inc. | Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 |
| JP4498741B2 (ja) | 2001-12-24 | 2010-07-07 | アストラゼネカ アクチボラグ | オーロラキナーゼ阻害剤としての置換キナゾリン誘導体 |
| JP2003213463A (ja) | 2002-01-17 | 2003-07-30 | Sumitomo Chem Co Ltd | 金属腐食防止剤および洗浄液 |
| EP1496896A4 (en) | 2002-04-08 | 2007-10-31 | Merck & Co Inc | AKT INHIBITORS EFFECT |
| US6962995B2 (en) | 2002-07-10 | 2005-11-08 | E. I. Du Pont De Nemours And Company | Charge transport compositions and electronic devices made with such compositions |
| US7825132B2 (en) | 2002-08-23 | 2010-11-02 | Novartis Vaccines And Diagnostics, Inc. | Inhibition of FGFR3 and treatment of multiple myeloma |
| EP1549614A4 (en) | 2002-10-03 | 2008-04-16 | Targegen Inc | VASCULATORY AGENTS AND METHODS FOR THEIR APPLICATION |
| AR043059A1 (es) | 2002-11-12 | 2005-07-13 | Bayer Pharmaceuticals Corp | Derivados de indolil pirazinona utiles para el tratamiento de trastornos hiper-proliferativos |
| US7098332B2 (en) | 2002-12-20 | 2006-08-29 | Hoffmann-La Roche Inc. | 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones |
| DE602004021558D1 (de) | 2003-01-17 | 2009-07-30 | Warner Lambert Co | 2-aminopyridin-substituierteheterocyclen als inhibitoren der zellulären proliferation |
| EP1620413A2 (en) | 2003-04-30 | 2006-02-01 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| US7244739B2 (en) | 2003-05-14 | 2007-07-17 | Torreypines Therapeutics, Inc. | Compounds and uses thereof in modulating amyloid beta |
| BRPI0410633A (pt) | 2003-05-23 | 2006-06-13 | Zentaris Gmbh | piridopirazinas e uso das mesmas como moduladores de cinase |
| DE10323345A1 (de) | 2003-05-23 | 2004-12-16 | Zentaris Gmbh | Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren |
| WO2005007099A2 (en) | 2003-07-10 | 2005-01-27 | Imclone Systems Incorporated | Pkb inhibitors as anti-tumor agents |
| WO2005009437A1 (en) | 2003-07-21 | 2005-02-03 | Bethesda Pharmaceuticals, Inc. | Design and synthesis of optimized ligands for ppar |
| CA2534649A1 (en) | 2003-08-01 | 2005-02-10 | Genelabs Technologies, Inc. | Bicyclic imidazol derivatives against flaviviridae |
| DE602004008312T2 (de) | 2003-10-17 | 2008-04-17 | 4 Aza Ip Nv | Heterocyclus-substituierte pteridin-derivate und ihre verwendung in der therapie |
| CN102225926A (zh) * | 2003-11-07 | 2011-10-26 | 诺华疫苗和诊断公司 | 具有改进药物特性的喹啉酮类化合物的药学上可接受的盐 |
| NZ546991A (en) * | 2003-11-20 | 2010-01-29 | Janssen Pharmaceutica Nv | 6-Alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as PARP inhibitors |
| SG150533A1 (en) | 2003-11-20 | 2009-03-30 | Janssen Pharmaceutica Nv | 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2- quinoxalinones as poly(adp-ribose) polymerase inhibitors |
| RU2377241C2 (ru) | 2003-11-24 | 2009-12-27 | Ф.Хоффманн-Ля Рош Аг | Производные пиразоло-имидазопиримидина, обладающие антагонистической активностью в отношении кортикотропин-рилизинг фактора (crf) |
| KR101164258B1 (ko) | 2003-12-23 | 2012-07-11 | 아스텍스 테라퓨틱스 리미티드 | 단백질 키나아제 조절제로서의 피라졸 유도체 |
| US7098222B2 (en) | 2004-05-12 | 2006-08-29 | Abbott Laboratories | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents |
| US7205316B2 (en) | 2004-05-12 | 2007-04-17 | Abbott Laboratories | Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands |
| AU2005278959A1 (en) | 2004-08-31 | 2006-03-09 | Astrazeneca Ab | Quinazolinone derivatives and their use as B-Raf inhibitors |
| BRPI0516488A (pt) | 2004-10-14 | 2008-09-09 | Hoffmann La Roche | azolidinonas de 1,5-naftiridina tendo atividade antiproliferativa de cdk1 |
| PL1830869T3 (pl) | 2004-12-24 | 2013-11-29 | Novartis Ag | Sposób leczenia lub profilaktyki |
| NZ556686A (en) | 2005-02-14 | 2010-01-29 | Bionomics Ltd | Novel tubulin polymerisation inhibitors |
| US9271963B2 (en) | 2005-03-03 | 2016-03-01 | Universitat Des Saarlandes | Selective inhibitors of human corticosteroid synthases |
| AU2006247833A1 (en) | 2005-05-12 | 2006-11-23 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| CA2608362A1 (en) | 2005-05-18 | 2006-11-23 | Wyeth | 4, 6-diamino-[1,7] naphthyridine-3-carbonitrile inhibitors of tpl2 kinase and methods of making and using the same |
| GB0513692D0 (en) | 2005-07-04 | 2005-08-10 | Karobio Ab | Novel pharmaceutical compositions |
| EA015937B1 (ru) | 2005-08-26 | 2011-12-30 | Мерк Сероно С.А. | Производные пиразина и их применение в качестве ингибиторов pi3k |
| EP1790342A1 (de) | 2005-11-11 | 2007-05-30 | Zentaris GmbH | Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege |
| KR101400905B1 (ko) | 2005-11-11 | 2014-05-29 | 아에테르나 젠타리스 게엠베하 | 신규한 피리도피라진 및 키나제의 조절제로서의 이의 용도 |
| US8217042B2 (en) | 2005-11-11 | 2012-07-10 | Zentaris Gmbh | Pyridopyrazines and their use as modulators of kinases |
| ES2612377T3 (es) | 2005-12-21 | 2017-05-16 | Janssen Pharmaceutica N.V. | Triazolopiridazinas como moduladores de tirosina cinasas |
| EP2024342A2 (en) | 2006-05-01 | 2009-02-18 | Pfizer Products Incorporated | Substituted 2-amino-fused heterocyclic compounds |
| GB0609621D0 (en) | 2006-05-16 | 2006-06-21 | Astrazeneca Ab | Novel co-crystal |
| US20100234347A1 (en) | 2006-05-24 | 2010-09-16 | Boehringer Ingelheim Internationl Gmbh | Substituted Pteridines substituted with a Four-Membered Heterocycle |
| WO2008003702A2 (en) | 2006-07-03 | 2008-01-10 | Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg | Fused bicyclic compounds interacting with the histamine h4 receptor |
| JP2008127446A (ja) | 2006-11-20 | 2008-06-05 | Canon Inc | １，５−ナフチリジン化合物及び有機発光素子 |
| NZ578329A (en) | 2006-12-13 | 2012-05-25 | Schering Corp | Igf1r inhibitors for treating cancer |
| US7872018B2 (en) | 2006-12-21 | 2011-01-18 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
| EP2114941B1 (en) | 2006-12-22 | 2015-03-25 | Astex Therapeutics Limited | Bicyclic heterocyclic compounds as fgfr inhibitors |
| KR20090092287A (ko) | 2006-12-22 | 2009-08-31 | 노파르티스 아게 | Ｐｄｋ１ 억제를 위한 퀴나졸린 |
| KR20080062876A (ko) | 2006-12-29 | 2008-07-03 | 주식회사 대웅제약 | 신규한 항진균성 트리아졸 유도체 |
| EP1990342A1 (en) | 2007-05-10 | 2008-11-12 | AEterna Zentaris GmbH | Pyridopyrazine Derivatives, Process of Manufacturing and Uses thereof |
| JP2010526823A (ja) | 2007-05-10 | 2010-08-05 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | Ｐｉ３キナーゼ阻害物質としてのキノキサリン誘導体 |
| WO2008150827A1 (en) | 2007-05-29 | 2008-12-11 | Smithkline Beecham Corporation | Naphthyridine, derivatives as p13 kinase inhibitors |
| AR066879A1 (es) | 2007-06-08 | 2009-09-16 | Novartis Ag | Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus |
| EP2172450B9 (en) | 2007-06-20 | 2014-10-08 | Mitsubishi Tanabe Pharma Corporation | Novel malonic acid sulfonamide derivative and pharmaceutical use thereof |
| WO2008155378A1 (en) | 2007-06-21 | 2008-12-24 | Janssen Pharmaceutica Nv | Polymorphic and hydrate forms, salts and process for preparing 6-{difluoro[6-(1-methyl-1h-pyrazol-4-yl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}quinoline |
| JP2010535804A (ja) | 2007-08-09 | 2010-11-25 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | Ｐｉ３キナーゼ阻害薬としてのキノキサリン誘導体 |
| WO2009019518A1 (en) | 2007-08-09 | 2009-02-12 | Astrazeneca Ab | Pyrimidine compounds having a fgfr inhibitory effect |
| US20090054304A1 (en) | 2007-08-23 | 2009-02-26 | Kalypsys, Inc. | Heterocyclic modulators of tgr5 for treatment of disease |
| AU2008321046B2 (en) | 2007-11-16 | 2013-10-24 | Incyte Holdings Corporation | 4-pyrazolyl-N-arylpyrimidin-2-amines and 4-pyrazolyl-N-heteroarylpyrimidin-2-amines as janus kinase inhibitors |
| CA2722992A1 (en) | 2008-05-05 | 2009-11-12 | Schering Corporation | Sequential administration of chemotherapeutic agents for treatment of cancer |
| NZ588511A (en) * | 2008-05-23 | 2012-04-27 | Novartis Ag | Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors |
| JP2012509342A (ja) | 2008-11-20 | 2012-04-19 | オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド | 置換ピロロ［２，３−ｂ］−ピリジンおよび−ピラジン |
| US8716280B2 (en) | 2009-01-21 | 2014-05-06 | Basilea Pharmaceutica Ag | Bicyclic antibiotics |
| AU2010208480A1 (en) | 2009-02-02 | 2011-07-28 | Msd K.K. | Inhibitors of Akt activity |
| TW201041888A (en) | 2009-05-06 | 2010-12-01 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| CN106928205B (zh) * | 2009-06-12 | 2019-09-24 | Abivax公司 | 用于治疗过早衰老和尤其是早衰的化合物 |
| MX2012002274A (es) | 2009-09-03 | 2012-09-07 | Bioenergenix | Compuestos heterociclicos para la inhibicion de pask. |
| CA2772790C (en) | 2009-09-04 | 2017-06-27 | Benjamin Bader | Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors |
| US20110123545A1 (en) | 2009-11-24 | 2011-05-26 | Bristol-Myers Squibb Company | Combination of vegfr2 and igf1r inhibitors for the treatment of proliferative diseases |
| EP2332939A1 (en) | 2009-11-26 | 2011-06-15 | Æterna Zentaris GmbH | Novel Naphthyridine derivatives and the use thereof as kinase inhibitors |
| SG184243A1 (en) | 2010-03-30 | 2012-10-30 | Verseon Corp | Multisubstituted aromatic compounds as inhibitors of thrombin |
| GB201007286D0 (en) * | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| WO2011146591A1 (en) | 2010-05-19 | 2011-11-24 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
| CN103153062B (zh) | 2010-05-24 | 2015-07-15 | 因特利凯有限责任公司 | 杂环化合物及其用途 |
| GB201020179D0 (en) | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
| CN102532141A (zh) | 2010-12-08 | 2012-07-04 | 中国科学院上海药物研究所 | [1，2，4]三唑并[4，3-b][1，2，4]三嗪类化合物、其制备方法和用途 |
| TW201309700A (zh) | 2011-01-31 | 2013-03-01 | Novartis Ag | 新穎雜環衍生物 |
| US9295673B2 (en) | 2011-02-23 | 2016-03-29 | Intellikine Llc | Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof |
| WO2012118492A1 (en) | 2011-03-01 | 2012-09-07 | Array Biopharma Inc. | Heterocyclic sulfonamides as raf inhibitors |
| AU2012300317B2 (en) | 2011-08-26 | 2016-12-01 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| CN104080455B (zh) | 2011-09-14 | 2018-07-31 | 润新生物公司 | 某些化学实体、组合物及方法 |
| EP2757885B1 (en) | 2011-09-21 | 2017-03-15 | Neupharma, Inc. | Certain chemical entites, compositions, and methods |
| AU2012318580A1 (en) | 2011-10-04 | 2014-05-22 | Gilead Calistoga Llc | Novel quinoxaline inhibitors of PI3K |
| JO3210B1 (ar) | 2011-10-28 | 2018-03-08 | Merck Sharp & Dohme | مثبط منصهر لبروتين نقل الكوليسترليستير اوكسازوليدينون ثمائي الحلقة |
| CN104039790B (zh) | 2011-10-28 | 2016-04-13 | 诺华股份有限公司 | 嘌呤衍生物及它们在治疗疾病中的应用 |
| GB201118654D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118675D0 (en) | 2011-10-28 | 2011-12-14 | Astex Therapeutics Ltd | New compounds |
| GB201118652D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| EA029140B1 (ru) | 2012-03-08 | 2018-02-28 | Астеллас Фарма Инк. | Новый слитый fgfr3 |
| GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| GB201209609D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| US20150203589A1 (en) | 2012-07-24 | 2015-07-23 | The Trustees Of Columbia University In The City Of New York | Fusion proteins and methods thereof |
| GB201307577D0 (en) | 2013-04-26 | 2013-06-12 | Astex Therapeutics Ltd | New compounds |
| US9221804B2 (en) * | 2013-10-15 | 2015-12-29 | Janssen Pharmaceutica Nv | Secondary alcohol quinolinyl modulators of RORγt |
| CN106456648B (zh) | 2014-03-26 | 2021-11-02 | 阿斯特克斯治疗有限公司 | Fgfr抑制剂和igf1r抑制剂的组合 |
| EP3848034A1 (en) | 2014-03-26 | 2021-07-14 | Astex Therapeutics Limited | Cmet-inhibitors for use in delaying the emergence in resistance to fgfr inhibitors |
| JO3512B1 (ar) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز |
| JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
-
2011
- 2011-10-28 GB GBGB1118652.5A patent/GB201118652D0/en not_active Ceased
-
2012
- 2012-10-26 CN CN201280065182.XA patent/CN104011025B/zh active Active
- 2012-10-26 MX MX2014004857A patent/MX353806B/es active IP Right Grant
- 2012-10-26 AU AU2012328164A patent/AU2012328164B2/en active Active
- 2012-10-26 DK DK12794744.8T patent/DK2776397T3/en active
- 2012-10-26 RU RU2014121494A patent/RU2625303C2/ru active
- 2012-10-26 CA CA2853366A patent/CA2853366C/en active Active
- 2012-10-26 HU HUE12794744A patent/HUE037458T2/hu unknown
- 2012-10-26 BR BR112014010177-9A patent/BR112014010177B1/pt active IP Right Grant
- 2012-10-26 JP JP2014537724A patent/JP6067725B2/ja active Active
- 2012-10-26 EP EP12794744.8A patent/EP2776397B1/en active Active
- 2012-10-26 IN IN988MUN2014 patent/IN2014MN00988A/en unknown
- 2012-10-26 WO PCT/GB2012/052666 patent/WO2013061074A1/en active Application Filing
- 2012-10-26 US US14/354,773 patent/US9439896B2/en active Active
- 2012-10-26 KR KR1020147010839A patent/KR102072869B1/ko active IP Right Grant
- 2012-10-26 ES ES12794744.8T patent/ES2661003T3/es active Active
-
2016
- 2016-07-08 US US15/205,676 patent/US10039759B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MX2014004857A (es) | 2014-08-26 |
| RU2625303C2 (ru) | 2017-07-13 |
| MX353806B (es) | 2018-01-30 |
| HUE037458T2 (hu) | 2018-09-28 |
| GB201118652D0 (en) | 2011-12-07 |
| EP2776397A1 (en) | 2014-09-17 |
| AU2012328164B2 (en) | 2017-08-03 |
| AU2012328164A1 (en) | 2014-05-15 |
| EP2776397B1 (en) | 2017-11-29 |
| ES2661003T3 (es) | 2018-03-27 |
| CN104011025A (zh) | 2014-08-27 |
| US20170000781A1 (en) | 2017-01-05 |
| CA2853366A1 (en) | 2013-05-02 |
| BR112014010177B1 (pt) | 2023-01-31 |
| US10039759B2 (en) | 2018-08-07 |
| US9439896B2 (en) | 2016-09-13 |
| JP2014530896A (ja) | 2014-11-20 |
| US20140296236A1 (en) | 2014-10-02 |
| CN104011025B (zh) | 2017-04-05 |
| DK2776397T3 (en) | 2018-02-26 |
| WO2013061074A1 (en) | 2013-05-02 |
| JP6067725B2 (ja) | 2017-01-25 |
| RU2014121494A (ru) | 2015-12-10 |
| CA2853366C (en) | 2021-04-20 |
| KR20140093665A (ko) | 2014-07-28 |
| KR102072869B1 (ko) | 2020-03-02 |
| BR112014010177A2 (pt) | 2017-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014MN00988A (hr) | ||
| IN2014MN00986A (hr) | ||
| IN2014MN00987A (hr) | ||
| IN2014MN00948A (hr) | ||
| IN2012MN02591A (hr) | ||
| IN2014MN02069A (hr) | ||
| IN2014MN02049A (hr) | ||
| PH12015501385A1 (en) | Autotaxin inhibitors | |
| PH12015500274A1 (en) | Alkylpyrimidine derivatives for the treatment of viral infections and further diseases | |
| PH12015500713B1 (en) | Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases | |
| MX2020010535A (es) | Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide. | |
| MX2014005928A (es) | Inhibidores ciclicos de glutaminasa. | |
| IN2014KN02601A (hr) | ||
| MX343706B (es) | Derivados heterocíclicos novedosos. | |
| IN2015DN01119A (hr) | ||
| IN2015DN01151A (hr) | ||
| IN2014MN00697A (hr) | ||
| IN2013DN02555A (hr) | ||
| IN2014DN03010A (hr) | ||
| UA110793C2 (uk) | Піразолілхіноксалінові інгібітори кінази | |
| TN2013000327A1 (en) | Novel heterocyclic derivatives |